Video

Dr. Saint Fleur-Lominy on Emerging Agents in MPNs

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health

Shella Saint Fleur-Lominy, MD, PhD, an assistant professor in the Department of Medicine at NYU Langone Health’s Perlmutter Cancer Center, discusses emerging agents in myeloproliferative neoplasms (MPNs).

Now that the field has a better understanding of the abnormal signals that occur in mutation-specific hematopoietic stem cells, more drugs are beginning to emerge, explains Saint Fleur-Lominy. For example, alisertib, which is an Aurora kinase A inhibitor, can reduce myelofibrosis in the bone marrow. In a phase I trial, alisertib led to a reduction in spleen size and improvement in symptoms similar to what is seen with JAK2 inhibitors. Out of 7 patients, 5 experienced a decrease in the amount of fibrosis that they had in the bone marrow, says Saint Fleur-Lominy.

A phase II study is evaluating the telomerase inhibitor telomeric oligonucleotide. Data demonstrated a slight reduction in spleen size and symptoms. Furthermore, investigators reported increased benefit with higher doses of the drug, adds Saint Fleur-Lominy.

Several other pathways, as well as the development of more specific JAK1/2 inhibitors, are under investigation, concludes Saint Fleur-Lominy.

Related Videos
Alfred L. Garfall, MD, MS
Razane El Hajj Chehade, MD
Mark Juckett, MD, professor, medicine, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School
Coral Olazagasti, MD
Barbara Jane O’Brien, MD, associate professor, Neuro-Oncology, Department of Neuro-Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Tycel Phillips, MD
Giuseppe Curigliano, MD, PhD
Timothy Hughes, MD, MBBS, FRACP, FRCPA
Andrew Davis, MD
Noa Biran, MD